Appointment Adds Key Population Health and Medication Management Expertise to Genomind as Population Health Tools are Launched
KING OF PRUSSIA, PA. November 9 2021 – Genomind®, a leading precision healthcare company, has named David Nash, MD, MBA the newest member of its Scientific Advisory Board (SAB).
Dr. Nash joins Genomind from the Jefferson College of Population Health at Thomas Jefferson University, where he serves as the Founding Dean Emeritus and the Dr. Raymond C. & Doris Grandon Professor of Health Policy. A board-certified internist, Dr. Nash is internationally recognized for his work in public accountability for outcomes, physician leadership development and quality-of-care improvement.
Dr. Nash is a principal faculty member for quality-of-care programming for the American Association for Physician Leadership (AAPL). Prior, he served on the NQF Task Force on Improving Population Health and the John M. Eisenberg Award Committee for The Joint Commission. He was also a founding member of the AAMC-IQ Steering Committee, the group charged with infusing the tenets of quality and safety into medical education. Dr. Nash has authored more than 100 peer-reviewed articles and edited 25 books, most recently Population Health: Creating a Culture of Wellness. Dr. Nash has delivered numerous endowed and named lectures across the country and currently serves as the Editor-in-Chief of the American Journal of Medical Quality, Population Health Management, and American Health and Drug Benefits.
Dr. Nash received his BA in economics (Phi Beta Kappa) from Vassar College, his MD from the University of Rochester School of Medicine and Dentistry, and his MBA in Health Administration (with honors) from the Wharton School at the University of Pennsylvania. While at Penn, Dr. Nash was a Robert Wood Johnson Foundation Clinical Scholar.
“I am privileged to join an amazing group of nationally prominent experts on the Genomind Scientific Advisory Board” said Dr. Nash. “I have been researching drug/drug interactions and medication errors for three decades and the powerful new tools developed by Genomind represent a watershed event to improve medication therapy across the entire spectrum of healthcare. I am looking forward to helping Genomind to get the right drug to the right patient at the right dose each and every time. These actions will necessarily improve the health of many populations, today and tomorrow.”
In addition to its flagship product, Genomind® Professional PGx Express™, Genomind recently launched GenMed✓Pro™, an interactive software tool that allows healthcare providers to select drugs that are less likely to cause gene-drug, drug-drug, and gene-drug-drug interactions. GenMed✓Pro, scores interactions between hundreds of medications and a dozen genes to produce an intuitive analysis of an individual’s entire drug profile. It also ranks alternative medications, so that a clinician is informed on not only the severity of an interaction, but also how to minimize these interactions. The logic in this software can be used to assess drug interactions in large populations, and will have relevance for payers, accountable care organizations and other entities responsible for delivery of health care to large populations.
“Population health refers to the distribution of health outcomes, resources, and equity within a population” said David Krause, MD, FACP, Co-CEO of Genomind. “Genomind’s expertise in pharmacogenetics is well suited to advancing the quadruple aim of improving the individual patient experience, improving health outcomes of populations, improving clinician satisfaction, and reducing the cost and resource utilization of health care. Dr. Nash is a national leader in population health, and his appointment brings expertise of the highest caliber to the core of Genomind’s leadership. We are proud to have him join our SAB.”
Originally published to Business Wire